Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21478312 | 0.80 | — | — | |
| SCHEMBL21478313 | 0.80 | CHRM2 (0.36) | CHRM2CHRM3ALOX5EPHX2 | |
| SCHEMBL21458042 | 0.77 | CHRM2 (0.35) | CHRM2CHRM3 | |
| SCHEMBL21471673 | 0.76 | PER2 (0.30) | — | |
| SCHEMBL20622402 | 0.76 | HPGD (0.42) | CHRM2CHRM3ALOX5EPHX2 | |
| SCHEMBL21471792 | 0.76 | CHRM2 (0.36) | CHRM2CHRM3 | |
| SCHEMBL20599068 | 0.75 | NOTUM (0.46) | CHRM2CHRM3 | |
| SCHEMBL21471714 | 0.75 | CHRM2 (0.38) | CHRM2CHRM3ALOX5EPHX2 | |
| SCHEMBL21471675 | 0.72 | ALDH1A1 (0.47) | CHRM2CHRM3 | |
| SCHEMBL21471683 | 0.72 | CHRM2 (0.36) | CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019199908-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |